Marico is an Indian FMCG company that makes money across personal care and foods, with a core coconut oil franchise (Parachute), value-added hair oils, Saffola edible oils, a fast-growing foods portfolio, and a digital-first premium personal care arm. In the latest quarter (Q1 FY27), India delivered 11% volume growth and 21% revenue growth, international business grew 15% in constant currency (Vietnam 27%, MENA 24%), and consolidated EBITDA margin expanded 40 bps year-on-year to 20.7%. The company has over 96% of its business gaining or sustaining market share, and over 99% gaining or sustaining penetration on a MAT basis. With revenue crossing INR10,000 crores and EBITDA margins around 20%, this is a high-quality consumer franchise, not a commodity player, though the base still has a large commodity-linked edible oil and coconut oil component that is being deliberately reduced over time.
The durability of Marico's economics rests on several reinforcing barriers that are visible in the data. Distribution reach via Project SETU has created a high-entry-barrier general trade network that smaller competitors cannot easily replicate, while the supply chain advantage in coconut oil, built over decades, allows Marico to gain share even when copra prices correct, as seen in Parachute's 400+ bps volume share gain in Q1 FY27. The organized coconut oil competitive set is acting rationally on pricing, and brand equity in hair oils and foods creates switching costs that protect repeat purchases. In digital-first categories like Beardo, Plix, and Cosmix, the company has demonstrated an ability to acquire and scale brands with loyal consumers and strong repeat rates, while managing LTV to CAC discipline. The shift from unbranded to branded, aided by GST rationalization, further tilts the field toward incumbents with distribution muscle and deep pockets.
The inflection is already underway and will define the 18-24 month picture. Management has guided FY27 to cross INR15,000 crores revenue with high-teen EBITDA growth, aspiring to 20% EBITDA growth. The commissioning of a INR500 crore greenfield plant in Q2 FY27 adds capacity for future growth. By FY28, revenue should be comfortably above INR17,000 crores, with new businesses (Foods and Premium Personal Care) expanding from 23% share in FY26 to around 30% as they target one-third by FY30. The digital-first portfolio is on track to exit FY27 at double-digit EBITDA margins, with Plix hitting double digits in 12-15 months and 4700BC EBITDA positive in 12-18 months, each moving toward mid-teens margins in three years. Gross margin is guided to expand 300-400 bps in FY27 over exit FY26, driven by copra prices roughly 35% below peak, and EBITDA margin should expand 140-150 bps this year, implying 22%+ by FY28. The almond oil franchise targets INR100 crores ARR by FY28, shampoo aims for near INR100 crores revenue this year, and cold-pressed oil becomes a sizable part of Saffola by next year, all contributing to mix shift away from commodity dependency.
Management has a consistent record of doing what it says. Across the last four calls, FY26 India volume growth of high-single to double-digit was met with quarterly prints of 9%, 11%, and 10%; Foods growth guided above 25% came in at 26% and 23%; international constant-currency growth guided at mid-teens delivered 14-16% each quarter; and the FY26 EBITDA margin compression from copra inflation was acknowledged and managed to a flat-to-up outcome. In Q1 FY27, the first quarter of the new fiscal, India volume growth of 11% beat the high single-digit guidance, and the company reaffirmed its aspiration to hit another double-digit volume quarter in the next three quarters. It raised the new business share target for FY27 from 25% to 27%, and maintains its Vision 2030 of INR20,000 crores revenue with mid-teens EBITDA growth. Capital allocation is disciplined: acquisitions like 4700BC, Cosmix, and Plix come with clear profitability milestones, and the company has not diluted shareholders to fund growth, relying on cash flow and a healthy balance sheet.
The quantified earnings path is clear: FY27 revenue of INR15,000 crores and 20% EBITDA growth, driven by volume recovery, premiumization, and margin expansion. For FY28-29, double-digit revenue growth should continue, with EBITDA margin expanding to the low-22% range as digital brands scale and commodity share falls. The key watchpoint is input cost inflation, specifically copra, crude-linked derivatives, and vegetable oils, which are up 60-70% for some commodities and could pressure the 300-400 bps gross margin assumption. If copra spikes again or crude/palm costs remain elevated, the margin expansion could be delayed. The kill shot is any sustained deviation from the guided EBITDA trajectory, particularly if the digital brands fail to reach double-digit margins on schedule or if competition in new categories like shampoo and supplements forces higher than planned A&P intensity. Should that happen, the thesis would shift from compounding to a slower growth story, but current data shows management has the playbook and the track record to execute, making the 18-24 month picture one of a larger, more profitable, and less commodity-exposed consumer group.
companyname: Marico Limited ticker: MARICO sector: Consumer Goods / FMCG (Beauty and Wellness) Marico Limited is an Indian FMCG company operating in beauty and wellness categories. In FY26 it generated consolidated revenue of INR13,611 crores, up 26% year on year, with recurring net profit of INR1,762 crores (Annual Report FY26). The India business accounts for roughly 76% of revenue; international operations contribute about 24% (Annual Report FY26). The India business has two layers. The cor...
Read the full report →capex, margin expansion, new product segment, acquisition inorganic
FY27 revenue growth guided at double-digit to cross INR15,000 crores; high-teen EBITDA growth by FY30 driven by digital-first portfolio scale-up and international diversification
Guidance no_dataconsistent
Get valuation models, detailed research reports, thematic primers, one-pagers, risk analysis, growth triggers, bear case, capex tracker, walk the talk, and more for Marico Limited and 4,900+ companies.
5-day free pass. No card required.